Skip to main navigation
Ventyx Biosciences, Inc. Ventyx Biosciences, Inc.
  • About
    • Overview
    • Leadership
    • Board of Directors
    • Advisory Board
    • Contact
  • Science
  • Pipeline
    • Overview
    • VTX958
    • VTX002
    • VTX2735
    • VTX3232
  • Investors
    • Overview
    • News & events
    • Stock information
    • Governance
    • Financials & filings
    • IR resources
  • Careers
  • News Releases
  • Events
  • Presentations

News Releases

News Releases

August 15, 2022
Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Read more
August 15, 2022
Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958
Read more
August 11, 2022
Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022
Read more
June 29, 2022
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735
Read more
June 1, 2022
Ventyx Biosciences to Participate in the Jefferies Healthcare Conference
Read more
May 12, 2022
Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Read more
May 9, 2022
Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer
Read more
May 5, 2022
Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022
Read more
March 23, 2022
Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress
Read more
March 7, 2022
Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference
Read more
  • First page «
  • Previous page ‹
  • Page 1
  • Current page 2
  • Page 3
  • Next page ›
  • Last page »
Displaying 11 - 20 of 26


Email Alerts


FAQ


Contact IR


RSS Feeds
Contact us
info@ventyxbio.com
  • Privacy Policy
  • Terms Of Use
© 2023 Ventyx Biosciences, Inc. All rights reserved.
linkedin
Ventyx Biosciences, Inc.